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Abstract: Levodopa (LD) is the oldest, most efﬁ  cacious and best-tolerated drug for dopaminergic 
substitution of patients with Parkinson’s disease (PD). Its main drawback is its short half-life, 
which supports onset of motor complications in the long term. Therefore well-informed PD 
patients mostly accept LD therapy as late as possible. Recent LD trials indicate that a combination 
of LD with carbidopa (CD) and the catechol-O-methyltransferase (COMT) inhibitor entacapone 
(EN) may reduce the onset of these motor complications to a certain extent. This observation is 
further supported by pharmacokinetic trials and experimental research, but there is still a need to 
conﬁ  rm this in a clinical trial, which is under way. Additionally, combined LD/CD/EN was supe-
rior to LD/CD administration regarding cognition, muscle behavior and gastrointestinal function 
in small clinical trials. Moreover there is accumulating evidence that combined COMT inhibition 
with LD administration reduces homocysteine synthesis. In the long term, homocysteine eleva-
tion supports onset of arteriosclerosis-related disorders, which are more frequent in PD patients 
according to epidemiological studies than in the normal healthy population. The introduction 
of LD/CD/EN in one tablet supported patients’ preference of COMT inhibition as an essential 
component of LD/DDI therapy, as this combination reduced number and size of tablets.
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Introduction
The oldest, most efﬁ  cacious and best tolerated drug for dopaminergic substitution 
therapy of patients with Parkinson’s disease (PD) is levodopa (LD).1 Initially LD was 
administered as infusion, then in oral form.2,3 LD administration was improved by the 
addition of the dopadecarboxylase inhibitors (DDI), such as carbidopa (CD), which 
reduces the peripheral degradation of LD to dopamine. This therapeutic principle 
supports LD metabolism via the enzyme catechol-O-methyltransferase (COMT) and 
delivers more LD to the brain.
LD/DDI and COMT inhibition
A further development was the introduction of COMT inhibitors, which decrease 
peripheral LD degradation to 3-O-methyldopa (3-OMD) and thus further increase the 
delivery of LD to the brain.4,5 Two COMT-inhibitors, the only peripheral-acting enta-
capone (EN) and the additionally central-acting tolcapone,6,7 are currently marketed as 
adjuncts to LD/DDI application. Both prolong the half-life of LD in the periphery.
Important clinical trials on the efﬁ  cacy 
of LD in PD patients
Out of the many investigations that demonstrated the efﬁ  cacy of LD, the Earlier vs 
Later L-DOPA (ELLDOPA) trial was the ﬁ  rst double blind trial, which compared the Patient Preference and Adherence 2009:3 52
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therapeutic efﬁ  cacy of LD/CD in 3 different daily dosages of 
150 mg, 300 mg or 600 mg with placebo treatment accord-
ing to the guidelines of good clinical practice (GCP) in 
PD patients. This trial conﬁ  rmed that LD is an efﬁ  cacious 
and well tolerated compound. Interestingly, this study also 
provided some evidence for progression-modifying beneﬁ  ts 
of LD in PD patients despite its relative short duration of 
approximately 9 months. After a washout interval of 14 days, 
the three cohorts of LD-treated PD patients performed better 
than the ones with prior placebo treatment. There is some 
evidence from experimental and clinical outcomes that the 
peripheral dual inhibition of both LD-metabolizing enzymes 
increases the LD delivery to the brain compared to LD/CD.8 
A further GCP trial on LD/CD efﬁ  cacy, the FIRST-STEP 
(Favorability of Immediate-Release Levodopa/Carbidopa vs 
STalevo Short-Term comparison in Early Parkinson’s dis-
ease) study, compared the efﬁ  cacy of 2 different modes of LD 
application, the conventional LD/CD administration versus 
LD/CD with the COMT inhibitor EN.9 This trial additionally 
aimed to demonstrate that the currently available triple com-
bination of LD/CD plus EN in 1 tablet (Stalevo®, Novartis) 
is safe in early PD patients with a need for LD therapy. This 
multicenter, double-blind, randomized, parallel-group study 
administered a ﬁ  xed oral LD dose of 300 mg/day, distributed 
as 100 mg LD doses 3 times daily at 5-hour intervals to 
424 PD patients. In this 39-week study, the PD patients in 
the LD/CD/EN arm performed signiﬁ  cantly better than the 
ones in the LD/CD-treated cohort after week four throughout 
the remaining course of the study. This was found when the 
sum scores of the UPDRS part II (Activities of daily living) 
and UPDRS part III (motor examination) were compared as 
the main primary outcome at the remaining study visits. The 
statistical analysis was performed with the intention to treat 
population and employed the last observation carried forward 
procedure. The frequency of nausea and diarrhea was higher 
in the LD/CD/EN arm due to the additional COMT inhibition 
with particularly diarrhea as a common side-effect.9 Thus the 
FIRST-STEP trial conﬁ  rmed the known additional LD/DDI 
efﬁ  cacy-enhancing effects of EN, when given as extra tab-
let, to an existing LD/CD regimen in treated PD patients.10 
However the design of the FIRST-STEP study lacked com-
parisons with placebo and treatment with dopamine agonists. 
One must realize that 300 mg LD/CD are not comparable to 
300 mg LD/CD/EN, since the additional COMT inhibition 
with EN delivers more LD to the brain and thus improves 
the clinical efﬁ  cacy of LD.
However both studies, FIRST-STEP and ELLDOPA, 
provide also some interesting ﬁ  ndings about the onset and 
frequency of ﬂ  uctuating disturbances of motor behavior, the 
so called motor complications, in PD patients. These symp-
toms are a serious drawback of LD therapy, and induce a lot 
of concern in PD patients and their caregivers and consider-
ably limit the acceptance of this compound.
Limitations of LD/DDI 
administration
There is a debate around mainly the clinical observation of 
the onset of ﬂ  uctuations of movement in the course of PD 
following the so called “honeymoon period” of LD therapy. 
Motor complications are predominantly associated with 
LD/DDI due to the short half-life of LD. They are looked 
upon as one essential clinical marker for the progression of 
PD. Peaks and troughs of plasma levels of LD and thus cor-
respondingly central striatal dopamine concentrations support 
occurrence of these initially predictable (which means depen-
dent on previous PD drug intake) and later unpredictable 
(independent of previous PD drug application) ﬂ  uctuations 
of movement. Clinically, they appear as involuntary motion 
sequences, the so-called dyskinesia, in the “ON” state. In 
contrast, “OFF” phenomena are characterized as temporary 
onset of the cardinal motor symptoms, akinesia, rigidity and 
tremor. They may indicate the decreasing efﬁ  cacy of the last 
dopaminergic drug intake before the next one. Then they are 
characterized as wearing-off phenomena.
Both kinds of motor complications are combined with 
appearance of a wide array of non-motor symptoms.1,11–13 
Various central-related hypotheses exist on the origin of 
these LD-associated motor complications. Loss of presyn-
aptic dopaminergic autoreceptor function with resulting 
non-physiologic high synaptic dopamine concentrations 
and consecutive altered postsynaptic dopamine receptor 
activation and further downstream intracellular changes 
currently is one of the most widely accepted hypotheses. 
There is accumulating evidence that continuous nigrostriatal 
postsynaptic dopaminergic receptor stimulation may prevent 
onset of motor complications.14
COMT inhibition and onset 
of motor complications
Additional COMT inhibition with LD/DDI application is 
also suspected of preventing motor complications since the 
rise and fall of LD and also accordingly of striatal dopamine 
are less intense during COMT inhibition, ie, with EN. This 
supports the concept of continuous dopaminergic stimulation 
due to a less ﬂ  uctuating delivery of LD to the brain.11,13–16 
Thus threshold problems of dopamine are reduced at striatal Patient Preference and Adherence 2009:3 53
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postsynaptic dopamine uptake sites. Therefore the frequency 
with which these receptors change between OFF and ON 
decreases.17–19 Accordingly, animal trials showed lower 
frequency and less intensity of manifestation of LD-associated 
motor complications in the long term, when a treatment with 
LD/DDI with the COMT inhibitor EN, given 4 times daily, 
was started right from the beginning.18 Further components 
for response variability to additional COMT inhibition and 
treatment of motor complications may be genetic features 
of the various COMT haplotypes. But no study has shown 
a clinical effect of the gene variations on the onset of motor 
complications and on the clinical efﬁ  cacy of LD.20,21
Onset of motor complications 
in the light of the FIRST -STEP 
and the ELLDOPA study
There is also some circumstantial evidence from the FIRST-
STEP and ELLDOPA study that COMT inhibition with 
EN also reduces the frequency of motor complications. 
The ELLDOPA study showed that the higher was the daily 
administered LD dose, the more frequent were motor compli-
cations. In this trial, the occurrence of motor complications 
were at the placebo level in the 150 mg daily LD dose-treated 
cohort. However, onset of motor complications rose up to 
3-fold in the 600 mg daily dose-treated group compared with 
placebo-treated PD patients (Table 1). In the FIRST-STEP 
trial, the number of monitored motor complications was 
higher in the LD/CD-treated arm in comparison with the LD/
CD/EN-treated PD cohort. It is known that less LD reaches 
the brain during LD/CD administration in comparison 
with LD/CD/EN administration. Therefore onset of motor 
complications cannot be attributed to the LD compound 
itself as initially thought in discussions on the neurotoxicity 
of LD. This observation suggests that the application mode 
is essential for the onset of motor complications. However 
the number of noted wearing-off phenomena and dyskinesia 
was rather low in relation to the size of the study cohort and 
the short observation interval (Table 2).9 A further conﬁ  rma-
tory result may be provided by the outcomes of the ongoing 
STRIDE-PD study. This trial aims to demonstrate that 
LD/CD/EN, when used as initial LD therapy, signiﬁ  cantly 
delays the time to onset of dyskinesia compared with the 
conventional LD/CD formulation. Nevertheless the optimum 
approach for LD therapy in view of the concept of continu-
ous dopaminergic stimulation is the LD patch, which failed 
probably due to an insufﬁ  cient design or side-effects, and the 
jejunal LD infusion. However this latter technique is expen-
sive, complex and needs constant caregiver supervision. 
Further improvement is still required, which is under way. 
But it is an efﬁ  cacious therapeutic option for treatment of 
motor complications in advanced PD patients.16 Therefore 
a further improvement of oral drug delivery is one of the 
essential goals for LD/DDI therapy, as, to a considerable 
extent, LD efﬁ  cacy also depends on peripheral absorption 
and degradation mechanisms of LD.
Components that inﬂ  uence 
peripheral LD bioavailability
Plasma bioavailability of LD is inﬂ  uenced by body weight, 
previous LD intake in a chronic fashion and by gastric 
emptying of the LD tablet to the duodenal and jejunal tract, 
where LD absorption takes place.22–25 But PD patients often 
receive a drug combination therapy that involves multiple 
daily dosing of a particular compound and additional sup-
plementation with other drugs at least partially sharing the 
modes of action. Efﬁ  cacy of all administered compounds 
depends on patient compliance, the nature of the delivery 
system, physicochemical properties of the drug and physi-
ological considerations. All of these are interrelated and 
affect the rate at which the drug is absorbed throughout the 
gastrointestinal tract and thus its bioavailability and pharma-
cokinetic proﬁ  le.26 In this respect EN improves the properties 
and dose of LD/DDI by prolonging the half-life of LD. But 
COMT inhibition may also promote the synthesis of more 
basic LD metabolites, ie, the tyrosine aminotransferase-
dependent substrates dihydroxyphenylpyruvate acetate 
and trihydroxyphenylacetate. Therefore COMT inhibition 
may model the environmental pH and the physicochemi-
cal properties of LD for its duodenal absorption. COMT is 
located in higher concentrations in the membranes of the 
Table 2 Rate of motor complications in the FIRST-STEP trial (%)
LD/CD/EN LD/CD Total
Dyskinesia 2.7 4.2 3.5 week 39
Wearing off 8.8 12.0 10.4 week 39
Dyskinesia 5.3 7.4 6.4 at any study visit
Wearing off 13.9 20 17 at any study visit
Table 1 Frequency of motor complications in the ELLDOPA trial (%)
LD/CD LD/CD LD/CD
150 mg 300 mg 600 mg placebo
Dyskinesia 3.3 2.3 16.5 3.3
Wearing off 16.3 18.2 29.7 13.3Patient Preference and Adherence 2009:3 54
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gastrointestinal tract.26–30 Generally, these physicochemical 
properties of a drug also affect its absorption through the 
gastrointestinal tract.26,31 Compounds including LD are 
weak bases or weak acids or are the salts of these, and as 
such demonstrate pH-dependent solubility. The pH partition 
hypothesis asserts that the passage rate of a drug through a 
membrane is dependent on the environmental pH and pKa 
of the drug. Drugs with low pKa are not ionized in the stom-
ach and subsequently rapidly absorbed. On passage to the 
small intestine with comparatively increased pH, the rate of 
ionization is changed and absorption subsequently slowed. 
The converse is true for drugs with higher pKa value. This 
inﬂ  uences the bioavailability of hydrophilic drug formula-
tions. They have a narrow window of absorption, limited 
predominantly to the stomach or the upper intestine. Absorp-
tion is also limited by low pKa value and/or the site of active 
transport absorption mechanism, as in the case of LD.26,31,32 
Additionally, absorption behavior of orally administered LD 
also depends on gastrointestinal transit rates, since uptake of 
LD occurs mainly in the proximal third of the small intestine 
(duodenum/jejunum) but not in the stomach. Intestinal LD 
absorption is rapid and complete, but the plasma bioavail-
ability of LD is only 30% as a result of prior degradation 
to dopamine by DDI and to a lesser extent to 3-OMD by 
COMT, ie, in the gut membranes. The longer LD is retained 
in the stomach and in the small intestine the more extensively 
it is metabolized and made less available for absorption.25 
A formulation that shares the peripheral absorption site 
proﬁ  le of LD, is sodium-octanoate, which is employed as 
[13C] marked substrate in breath tests. These investigations 
are a non-invasive, feasible, alternative method without 
ionizing radiation to measure gastric emptying of solids 
and liquids. After intake, [13C]-sodium-octanoate is rapidly 
absorbed from the proximal intestine and carried to the 
liver via the portal venous system. There it is oxidized and 
eliminated as CO2 in the breath, reﬂ  ecting gastric empty-
ing as the rate-limiting step of the process. Accordingly, 
signiﬁ  cant associations between pharmacokinetic plasma 
behavior of LD and the outcomes of the [13C]-octanoic acid 
breath test (OBT) appeared. In this study no impact of EN 
addition on gastric emptying time was found. But COMT 
inhibition with EN increased the recovery rate of the salt 
[13C]-sodium-octanoate.25,29,30
The anti-acid scenario of COMT 
inhibition
It is known that medicaments are better absorbed with a 
rise in pH due to the dramatically improved solubility. 
This results in a complete dissolution of the substance, which 
makes it readily available for absorption.26,32 Conventional 
LD/DDI is mainly metabolized to derivatives which 
lower the pH value. The main substrate is vanillic acid. 
This is formed from the initial tyrosine aminotransferase-
dependent derivative dihydroxyphenylpyruvate followed by 
a COMT-dependent second metabolic step. An alternative 
pathway for the formation of vanillic acid is the COMT-
triggered degradation of LD to 3-OMD with a subsequent 
tyrosine aminotransferase-dependent second step. A further 
metabolite is homovanillic acid, since this depends on the 
initial DDI-dependent conversion to dopamine. However 
this LD derivative may play a minor role, since a DDI is 
mostly applied nowadays with LD. Dopamine is metabo-
lized to the initial MAO-dependent dihydroxyphenyl-
acetic acid or as an alternative to the COMT-dependent 
3-methroxytyramine. Both dihydroxyphenylacetic acid 
via COMT and 3-methroxytyramine via monoaminooxi-
dases are then transformed to homovanillic acid. During 
LD/CD/EN administration, LD is mainly degraded to the 
tyrosine aminotransferase-dependent substrates dihydroxy-
phenylpyruvate acetate and trihydroxyphenylacetate and to 
a distinctly lesser extent to dihydroxyphenylacetic acid in 
the periphery.33 This more basic milieu may hypothetically 
inﬂ  uence the activity of the intestinal H+-coupled nutrient, 
micronutrient and drug transporters in the mammalian 
small intestine and thus enable a better transport of acids 
into the peripheral blood circulation.26,31,32 Previous studies 
showed no effect of acute COMT inhibition with EN on 
gastric emptying. But these investigations did not exclude 
the possibility that repeat application of EN may inﬂ  uence 
the gastric emptying rate and further increase the bioavail-
ability of co-administered substances.24,25,34 With LD, this 
may cause a deteriorated degradation and result in higher 
LD concentrations in the gastrointestinal membranes due 
to the simultaneous blocking of COMT by EN and DDI 
by CD. Since LD itself may contribute to delayed gastric 
emptying rate, this may result in the observed smoother 
increase of LD concentrations after repeat EN application. 
But these investigations support the conclusion that COMT 
inhibition combined with LD/DDI does not alter absorption 
of co-administered salts probably due to COMT inhibition-
induced basic environment in gastrointestinal membranes. 
This improves dissolution and absorption of acids and salts 
and may therefore enhance the absorption and efﬁ  cacy of 
LD.24,25,34 It will remain speculative whether this more basic 
scenario may also contribute to a better patient acceptance 
due to a lower incidence of gastrointestinal disturbances, Patient Preference and Adherence 2009:3 55
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such as pyrosis. However it may also inﬂ  uence function 
of muscles.
COMT inhibition and muscle 
function
LD/CD application increases grip strength after standard-
ized application and thus increases muscular strength in PD 
patients. LD/CD intake counteracts muscle weakness and 
thus indirectly also improves grip forces during both lifting 
and holding of a subject in an instrumental grip force para-
digm in PD patients.35 This may result from LD/CD-induced 
improvement of bradykinesia and rigidity. But referring to 
the impact of LD/CD on grip force, 150 mg LD/CD/EN was 
superior to the 200 mg slow release LD/CD formulation. Both 
LD formulations exhibited similar plasma pharmacokinetics 
of LD and clinical efﬁ  cacy in terms of improvement of motor 
symptoms after standardized one time application. The 
LD/CD/EN-associated anti-acid scenario after LD/CD/EN 
intake may contribute to more basic pH values in skeletal 
muscles.25,33–36 This may support muscle function, since 
generation of acidic H+ ions, which are commonly attributed 
to the formation of organic acids such as primarily lactic 
acid, is buffered. As a result muscle excitability and con-
tractibility improves. Both could have contributed to the 
observed augmented grip strength after LD/CD/EN intake 
in comparison with LD/CD administration.25,34–36 This trial 
underlined the importance of COMT inhibition in addition 
to LD/CD administration in PD patients beyond the impact 
of LD/CD on motor symptoms. A further important issue 
is the role of the 3-OMD, when LD/DDI is given with and 
without COMT inhibition.
COMT inhibition and 3-OMD 
metabolism
COMT inhibition reduces 3-OMD plasma concentrations. 
This could have inﬂ  uenced the attention-related components 
of an instrumental task performance, the line tracing test. In 
this trial, 150 mg LD/CD/EN was superior to 200 mg slow 
release LD/CD after standardized one time administration. 
There was no rise of 3-OMD during the LD/CD/EN admin-
istration but there was after LD/CD intake.36 Therefore more 
LD was delivered to the brain during LD/CD/EN administra-
tion, since 3-OMD competes with LD during transport over 
the blood–brain barrier. Thus 3-OMD may interfere with the 
LD response by inhibiting tyrosine uptake in the striatum 
and subsequent LD utilization, which inhibits metabolism 
of LD to dopamine.37,38 It is known that small changes in 
catecholamine modulation of prefrontal cortex cells can 
have profound effects on the ability of the prefrontal cortex 
to guide behavior.39 Therefore this small difference of LD 
delivery to the prefrontal cortex could have been responsible 
for the described signiﬁ  cant difference in the attention-
related components of the line tracing task in favor of the 
LD/CD/EN condition. In contrast, the basal ganglia may 
better tolerate and compensate ﬂ  uctuations of dopamine 
levels. However there are further metabolic aspects associ-
ated with a decreased 3-OMD synthesis, which is associated 
with homocysteine synthesis.
LD/DDI formulations, 3-OMD 
and homocysteine
LD applied only with a DDI increases homocysteine in 
plasma.40 This may support the onset of atherosclerosis-
related disorders, which has been shown in PD patients by 
epidemiological studies.41,42 To date, this LD-related homo-
cysteine elevation has been considered as a long-term side 
effect in terms of onset of clinical consequences, ie, increase 
of vascular disease-related thickening of the intima media 
complex, and elevated risk of more neuropsychiatric compli-
cations, ie, depression and deteriorated cognitive function, in 
PD patients in earlier studies.43–46 However the outcomes of 
more recent trials were only partially conﬁ  rmatory.47,48 This 
may be due to a relative low number of participants, and 
design and duration of these studies. Moreover the vitamin B 
and folic acid status and variations of the distribution of the 
polymorphism of the methylenetetrahydrofolate reductase 
(MTHFR) gene may play a role in the various investigated 
cohorts. In particular, the homocygote MTHFR T/T allele 
promotes elevated homocysteine levels.43,49,50 But one must 
clearly state that a relationship between homocysteine 
levels and deleterious consequences in PD, for instance 
stroke or cognitive decline, has not been conclusively 
demonstrated.
Therapy of homocysteine elevation 
with COMT inhibition
An approach for homocysteine decrease in plasma is 
application of COMT inhibitors as adjunct to LD/DDI 
formulations, as this combination reduces O-methylation of 
LD. Addition of the COMT inhibitor tolcapone to a stable 
antiparkinsonian drug regime reduced homocysteine plasma 
levels. This small prospective trial provided some evidence 
that COMT inhibition lowers homocysteine generation.51 
In rats, this was also shown with the peripherally acting 
COMT inhibitor EN.52 Clinical data of EN in humans 
are still under discussion. There are prospective negative Patient Preference and Adherence 2009:3 56
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studies, but they may have been under powered because 
of folate supplementation in the American and Canadian 
diet, leading to a milder increase in homocysteine than 
expected.44,53,54 Observational European non-prospective 
studies showed lower homocysteine levels in EN-treated 
patients.55–57
Homocysteine metabolism 
in relation to peripheral and central 
COMT inhibition
These ﬁ  ndings warrant a discussion about which COMT 
inhibitor, EN or tolcapone, is more suitable for modulating 
homocysteine synthesis. In contrast to the controversial 
results for EN acting only in the periphery, tolcapone even 
reduced homocysteine levels following repeated intake.51 
This may indicate a certain superiority of tolcapone over 
EN in terms of impact on homocysteine metabolism. But 
it may also result from the different study designs used. 
However there is an essential pharmacological discrepancy 
between both compounds, since tolcapone but not EN 
also occurs and acts centrally.6,7 Thus tolcapone may even 
reduce homocysteine levels within the brain and thus the 
associated neurotoxic effects of homocysteine.58,59 Central 
COMT activation caused a sustained synthesis of homo-
cysteine in astrocytes and transport of this amino acid to 
neurons. This was blocked by COMT inhibition, which was 
seen as neuroprotective. Moreover glial COMT reduced 
N-methylation of the dopamine derivative salsolinol to 
N-methylsalsolinol or of the tetrahydroisoquinolines (TIQ) 
to the corresponding neurotoxic N-methylisoquinolinium 
ions.60–62 Therefore central COMT inhibition may turn out 
to be a double-edged sword, since the broad detoxiﬁ  cation 
potential of COMT within the brain is reduced. Thus exclu-
sive central COMT inhibition may also force central dopa-
mine degradation to metabolism via monoaminooxidase B, 
which generates oxidative stress. Therefore oxidative stress 
was found in combination with S-adenosylmethionine 
(SAM) depletion, as SAM is the methyl donor for nicotin-
amide N-methylation and most other important methylation 
reactions.7,61,63–66 Accordingly, reduced SAM levels were 
found in chronic neurodegeneration.67–70 LD/DDI further 
lowered SAM concentrations,71 as O-methylation of LD 
by COMT elevates homocysteine.58,64,72 Consequently, 
one may suggest combining central COMT inhibition 
with central blocking of monoaminooxidase-B. This may 
increase the generation of free radicals via monoami-
nooxidase A-induced dopamine degradation. Moreover 
this may further promote the shift from O-methylation to 
N-methylation, and a cumulative metabolism of dopamine 
and other substrates via N-methylating enzymes. As a 
result, an increment of neurotoxic N-methylated TIQs 
synthesis may occur, as shown in clinical studies.73,74 Only 
LD/DDI-treated but not untreated PD patients showed 
increased levels of N-methylated TIQs, but not of their 
corresponding metabolic precursors.75–78 Thus in conclu-
sion this increased risk of PD accelerating synthesis of 
free radicals and N-methylated TIQs associated with 
central COMT inhibition may suggest peripheral COMT 
inhibition as adjunct for LD/DDI therapy. This may also 
underline the safety of EN in the treatment of PD patients, 
which is one of the essentials for accepting the intake of 
a compound in the long term.
The safety of EN long-term 
application
Numerous trials and reviews have proven and reported 
the long-erm tolerability and safety of EN treatment in PD 
patients. The introduction of the triple combination LD/
CD/EN in one tablet is also safe and efﬁ  cacious. Combined 
EN application with selegiline, dopamine agonists and 
antidepressants such as imipramine was well tolerated.79–89 
Observed discoloration of the urine is harmless, but the patient 
should be informed before start of therapy by the treating 
physician. In contrast there was always a certain debate about 
putative peripheral and central toxic effects of tolcapone.63 
This was followed by reports that tolcapone causes onset of 
serious hepatic reactions with development of severe, some-
times fatal, hepatic disease as well as possible occurrence of 
rhabdomyolysis and neuroleptic malignant-like syndrome. 
One assumes that patients with mutations in the UDP-
glucuronosyltransferase 1A9 gene, which leads to defective 
glucuronidation activity, may be predisposed to COMT 
inhibitor-induced hepatotoxicity.90 Therefore tolcapone 
was temporarily withdrawn nearly all over the world. The 
most frequent non-dopaminergic adverse event of COMT 
inhibition was diarrhea, usually 2 to 4 months following 
treatment initiation. This may be due to the inhibition of 
5-HT metabolism in the gastrointestinal tract, which causes 
an increase of gastrointestinal motility in some PD patients.4,5 
Headache, increased sweating and associated xerostoma 
probably due to aggravation of dyskinesia in clinical trials, 
abdominal pain, and harmless urine discoloration are more 
frequently reported than in the placebo arm in clinical trials 
that tested the efﬁ  cacy of COMT inhibitors. But the discussion 
on the liver toxicity of tolcapone with a demand for regular 
liver function tests also biased the patients’ preference for Patient Preference and Adherence 2009:3 57
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EN intake. An additional negative criterion for tolcapone use 
is the need for a previous failed response to EN or intolerance 
of intake of other COMT inhibitors.
Aspects of patient preference 
for LD/CD combined with EN intake
Treatment of PD often requires intake of an increasing 
number of tablets with progression of the disease, which 
results in compliance problems. Therefore discipline and 
education of patients and their caregivers are essential tools 
to minimize any behavior that might limit the efﬁ  cacy of 
compounds.91,92 Advanced PD patients must often take LD 
doses more frequently (LD “fractionation”) and as continu-
ously as possible, since ﬂ  uctuations of plasma LD levels and 
accordingly motor performance should be reduced. In this 
regard the introduction of the triple combination LD/CD/EN 
in one tablet was an essential step forward in contrast to the 
older LD/DDI plus EN administration as an extra tablet. 
Now oral LD/CD/EN therapy requires intake of half the 
number of tablets. Moreover the pills of the LD/CD/EN 
formulation are distinctly smaller, which favors patients’ 
acceptance. A remaining drawback is the availability of this 
combination in only a few LD dosages, which limits the 
titration possibilities for the physician in comparison with 
LD/CD. This drawback should be remedied in the near future 
with the necessary introduction of 25 mg, 75 mg, 125 mg, 
175 mg LD/CD/EN formulations. However for titration 
speed, efﬁ  cacy and tolerability LD/CD/EN is superior to 
that of dopamine agonists, which still have the advantage 
of delaying the time to onset of motor complications, as 
proven by numerous studies and reviews.93,94 But one must 
realize that there is still a lack of data on patient preference 
and of comparative studies on other forms of LD, such as 
controlled-release formulations, on infusion application 
modes and on dopamine agonists.
Conclusion
Additional peripheral COMT inhibition with EN is an 
improvement on LD/DDI administration in PD patients. It 
contributes to a better cognition, muscle force and move-
ment behavior performance according to clinical outcomes. 
There is some evidence that peripheral COMT inhibition also 
delays onset of motor complications and supports occurrence 
of lower homocysteine plasma levels, which, when elevated, 
represent a risk factor for accelerated PD progression and 
arteriosclerosis. The triple combination LD/CD/EN in one 
tablet is an essential step forward, since pill size and number 
of tablets taken are reduced. This formulation improved 
patients’ acceptance and preference in addition to its proven 
better safety compared with tolcapone.
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